EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY-NC 3.0

Ensifentrine Added on to Dual Bronchodilator or Triple Therapy Demonstrates Clinically Meaningful Improvement in CAT Score in Symptomatic Patients with Chronic Obstructive Pulmonary Disease

Thomas M Siler iD, Tara Rheault, Daniel Reyner iD, Margot MacDonald-Berko iD, John Davidson, Kathleen Rickard iD

International Journal of Chronic Obstructive Pulmonary Disease · 2026

DOI: 10.2147/copd.s589655 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2026. Verfasst von Thomas M Siler und 5 weiteren Autor:innen. Beteiligte Einrichtung: Midwest Chest Consultants, PC, Saint Charles, MO, USA. Hauptthemen laut MEDLINE: Adrenergic beta-2 Receptor Agonists, Bronchodilator Agents, Lung, Muscarinic Antagonists. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Many patients with chronic obstructive pulmonary disease (COPD) remain symptomatic despite the use of available maintenance therapies. Ensifentrine is a novel, selective, dual inhibitor of phosphodiesterase (PDE)3 and PDE4 approved for use as a maintenance therapy in adult patients with COPD. This study evaluated the effect of ensifentrine added on to dual or triple therapy on symptoms and health status in symptomatic patients with COPD using the COPD Assessment Test™ (CAT).

Methods

In this single-center, Phase 3b, open-label study, patients aged 40 to 80 years with symptomatic (modified Medical Research Council Dyspnea Scale ≥2; CAT ≥10), moderate to severe COPD on stable dual bronchodilator or triple therapy received 3 mg twice-daily nebulized ensifentrine for 12 weeks. CAT scores were assessed at baseline, week 6, and week 12.

Results

Twenty eligible patients received ensifentrine. Patients with ≥1 postdose assessment (n=18) were analyzed. After 12 weeks, ensifentrine improved CAT scores by ≥2 units in 67.0% (95% CI, 38.0%, 100.0%) of patients. Mean change from baseline was -2.3 units (95% CI, -4.0, -0.6), exceeding the clinically important difference of -2 units. At week 6, 44.4% (95% CI, 22.0%, 89.5%) of patients were CAT responders; the mean change from baseline in CAT score was -1.5 units (95% CI, -4.0, 1.1). No adverse events were reported.

Conclusion

Ensifentrine provided clinically meaningful improvement in health status measured by CAT score in two-thirds of symptomatic patients with COPD taking dual bronchodilator or triple therapy in a real-world setting. Clinical Trial Registration Number: Clinical trial registered on June 10, 2024, with Clinicaltrials.gov (Identifier: NCT06460493).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenergic beta-2 Receptor AgonistsBronchodilator AgentsLungMuscarinic AntagonistsPhosphodiesterase 3 InhibitorsPhosphodiesterase 4 InhibitorsPiperidinesPulmonary Disease, Chronic ObstructivePyrimidinonesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAdministration, InhalationDrug Therapy, CombinationForced Expiratory VolumeHealth StatusRecovery of FunctionSeverity of Illness IndexTime FactorsTreatment OutcomeIsoquinolines

Stichwörter der Autor:innen

COPD Assessment Testchronic obstructive pulmonary diseaseensifentrinephosphodiesterase inhibitorquality of life

Substanzen

Adrenergic beta-2 Receptor AgonistsBronchodilator AgentsensifentrineMuscarinic AntagonistsPhosphodiesterase 3 InhibitorsPhosphodiesterase 4 InhibitorsPiperidinesPyrimidinonesIsoquinolines

Autor:innen und Institutionen

  • Midwest Chest Consultants, PC, Saint Charles, MO, USA.
  • Verona Pharma, a Subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
  • Stat One LLC, Cary, NC, USA.

ORCID-Profile: Thomas M Siler, Daniel Reyner, Margot MacDonald-Berko, Kathleen Rickard

Zitieren

APA

Siler, T. M., Rheault, T., Reyner, D., MacDonald-Berko, M., Davidson, J., & Rickard, K. (2026). Ensifentrine Added on to Dual Bronchodilator or Triple Therapy Demonstrates Clinically Meaningful Improvement in CAT Score in Symptomatic Patients with Chronic Obstructive Pulmonary Disease. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s589655

Vancouver

Siler TM, Rheault T, Reyner D, MacDonald-Berko M, Davidson J, Rickard K. Ensifentrine Added on to Dual Bronchodilator or Triple Therapy Demonstrates Clinically Meaningful Improvement in CAT Score in Symptomatic Patients with Chronic Obstructive Pulmonary Disease. International Journal of Chronic Obstructive Pulmonary Disease. 2026. doi:10.2147/copd.s589655

BibTeX
@article{Siler2026,
  author = {Siler, Thomas M and Rheault, Tara and Reyner, Daniel and MacDonald-Berko, Margot and Davidson, John and Rickard, Kathleen},
  title = {Ensifentrine Added on to Dual Bronchodilator or Triple Therapy Demonstrates Clinically Meaningful Improvement in CAT Score in Symptomatic Patients with Chronic Obstructive Pulmonary Disease},
  journal = {International Journal of Chronic Obstructive Pulmonary Disease},
  year = {2026},
  doi = {10.2147/copd.s589655}
}
Kostenlos starten →